Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?

Company Overview - Esperion Therapeutics (ESPR) shares have increased by approximately 28.6% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the stock's performance and potential catalysts [1] Earnings Estimates - Estimates for Esperion Therapeutics have trended downward, with the consensus estimate decreasing by 25.93% over the past month [2] - The overall direction of estimate revisions indicates a downward shift in expectations for the company [4] VGM Scores - Esperion Therapeutics has a Growth Score of B, a Momentum Score of F, and a Value Score of C, placing it in the middle 20% for the value investment strategy [3] - The aggregate VGM Score for the stock is D, which is relevant for investors not focused on a single strategy [3] Industry Performance - Esperion Therapeutics is part of the Zacks Medical - Drugs industry, which includes Ionis Pharmaceuticals (IONS) [5] - Ionis Pharmaceuticals has seen a 6.2% gain over the past month, with reported revenues of $132 million, reflecting a year-over-year increase of 10.9% [5] - Ionis Pharmaceuticals is expected to report a loss of $0.14 per share for the current quarter, showing a year-over-year improvement of 68.9% [6]